Latest Breaking News On - Oncology global product strategy - Page 2 : comparemela.com

FDA Approves Momelotinib to Treat Myelofibrosis Patients With Anemia

Most patients with myelofibrosis will develop anemia over the course of the disease, with more than 30% discontinuing treatment as a result.

United statesKapila vigesRubena mesaNina mojasNational centerAtrium health levine cancer centerResearch foundationNational institutes of healthTranslational sciencesOncology global product strategyAdvancing translationalNational institutesMyeloproliferative neoplasms

Ojjaara Approved for Intermediate or High-Risk Myelofibrosis With Anemia

Ojjaara Approved for Intermediate or High-Risk Myelofibrosis With Anemia
empr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from empr.com Daily Mail and Mail on Sunday newspapers.

Nina mojasDrug administrationSenior vice presidentOncology global product strategy

Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

16.09.2023 - GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis . Seite 1

Nina mojasDrug administrationSenior vice presidentOncology global product strategyGsk chartSk kursSk aktie

GSK plc: Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

GSK plc: Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesBaden wübergUnited kingdomCity ofUnited kingdom generalKathleen quinnNick stoneSteph mountifieldTim foleyAnn hematolCamilla campbellRubena mesaLyndsay meyerNina mojasSarah clementsJeff mclaughlin

GSK s Ojjaara approved in US for myelofibrosis patients with anaemia

GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the first and only treatment indicated for myelofibrosis patients with anaemia. The London-based.

City ofUnited kingdomNina mojasHeather rydingsAlliance news ltdUs food drug administrationAlliance newsOncology global product strategyDrug administrationAll rights